Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 23, 2020

Featured Resources for Glycan Analysis

N-Glycan Analysis: Better Together
In this brochure, you will learn about Agilent solutions for sample preparation for N-glycans to support your LC/FLD/MS and CE workflows.

Download the Brochure


Development of a Rapid 2-AB Sample Preparation Workflow for N-Glycan Release and Labeling
In this application note, we will present the development and application of a rapid N-glycan sample preparation workflow using a five-minute in solution deglycosylation step followed by direct on-matrix 2-AB labeling and cleanup. Without the need for a dry down step, samples are ready for analysis in approximately 2 hours.

Download the Application Note​


Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q-TOF
Access this application note to discover how our Q-TOF LC/MS solutions can help you in the analysis of glycoforms on the intact and reduced mAbs molecules as well as in the analysis of released glycan.

Download the Application Note​


Glycopeptide Characterization for Various Monoclonal Antibodies Using the Agilent 6545XT AdvanceBio LC/Q-TOF
In this application note, you will learn about glycopeptide analysis. This workflow shows results not only in glycan-relative quantitation, but also N-glycosylation site(s) information.

Download the Application Note​


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.